PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
PVCT.WS was delisted on the 13th of October, 2016.
3 hedge funds and large institutions have $540K invested in PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
20% less capital invested
Capital invested by funds: $675K → $540K (-$135K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$101 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $440K | – | – | – |
|
2
Millennium Management
New York
| $100K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| – | +$101 | +425 | New |
|
PVCT.WS Hedge Fund Activity: Q1 2016 in Review
3 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) (PVCT.WS) for Q1 2016, worth a combined $540K — down 20% from $675K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PVCT.WS positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $101.
- 3 institutional investors held PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) (PVCT.WS) as of Q1 2016, up from 2 in Q4 2015.
- Funds reported $540K of PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) stock for Q1 2016, down 20% quarter-over-quarter.
- 1 fund opened new PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) positions in Q1 2016 and 0 closed out, a net change of +1 holder.
- The largest PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) buyer in Q1 2016 was UBS Group, an estimated $101 added.
Based on aggregated 13F filings for Q1 2016.